tert-butyl N-ethyl-N-(pyrrolidin-3-yl)carbamate | 1120357-23-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl N-ethyl-N-(pyrrolidin-3-yl)carbamate
• 英文别名: (+/-)-3-[N-(tert-butoxycarbonyl)-N-ethyl]aminopyrrolidine；Ethyl-pyrrolidin-3-YL-carbamic acid tert-butyl ester；tert-butyl N-ethyl-N-pyrrolidin-3-ylcarbamate
• CAS: 1120357-23-4
• 化学式: C₁₁H₂₂N₂O₂
• mdl: MFCD11847974
• 分子量: 214.308
• InChiKey: YSSKLKKEUPUEEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl N-ethyl-N-(pyrrolidin-3-yl)carbamate 、 4-bromo-2-ethyl-N-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}indazole-7-carboxamide 在 caesium carbonate 、 三氟乙酸 、 2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 2-ethyl-4-[3-(ethylamino)pyrrolidin-1-yl]-N-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}indazole-7-carboxamide
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS FOR MODULATING SPLICING
  [FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DE L'ÉPISSAGE

  摘要：

  The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.

  公开号：

  WO2023034812A1

文献信息

• [EN] INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF<br/>[FR] DÉRIVÉS D'INDAZOLYL-SPIRO [2.2] PENTANE-CARBONITRILE EN TANT QU'INHIBITEURS DE LRRK2, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：MERCK SHARP & DOHME

  公开号：WO2019074809A1

  公开（公告）日：2019-04-18

  The present invention is directed to substituted certain reversed indazolyl-spiro[2.2]pentane-carbonitrile derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及Formula (I)的某些取代的反转吲哚基螺[2.2]戊烷-碳腈衍生物及其药学上可接受的盐，其中R1、R2、R3、X、Y和Z如本文所定义，这些衍生物是LRRK2激酶的有效抑制剂，可能在治疗或预防LRRK2激酶参与的疾病中有用，如帕金森病和本文所述的其他疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗LRRK-2激酶参与的这些疾病中使用这些化合物和组合物。
• Pleuromutilin derivatives having a purine ring. Part 3: Synthesis and antibacterial activity of novel compounds possessing a piperazine ring spacer
  作者：Yoshimi Hirokawa、Hironori Kinoshita、Tomoyuki Tanaka、Takanori Nakamura、Koichi Fujimoto、Shigeki Kashimoto、Tsuyoshi Kojima、Shiro Kato

  DOI：10.1016/j.bmcl.2008.10.127

  日期：2009.1

  the water-soluble thioether pleuromutilin analogue 6, which has excellent in vitro and in vivo antibacterial activities, led to discovery of the novel pleuromutilin derivatives having a piperazine ring spacer. These derivatives displayed potent and well-balanced in vitro antibacterial activity against various drug-susceptible and -resistant Gram-positive bacteria. In particular, the promising pleuromutilin

  对具有优异的体外和体内抗菌活性的水溶性硫醚截短侧耳素类似物6的SAR研究导致发现了具有哌嗪环间隔基的新型截短侧耳素衍生物。这些衍生物显示出对各种药物敏感性和耐药性革兰氏阳性细菌有效且均衡的体外抗菌活性。特别地，发现有希望的截短侧耳素类似物37和40表现出针对金黄色葡萄球菌史密斯的强体内功效。
• WO2023/133225
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] COMPOUNDS AND METHODS FOR MODULATING SPLICING<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DE L'ÉPISSAGE
  申请人：[en]REMIX THERAPEUTICS INC.

  公开号：WO2023034812A1

  公开（公告）日：2023-03-09

  The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.